- Home
- NRSN vs RAND Comparison
NRSN vs RAND Comparison
Compare NRSN & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRSN | RAND |
|---|---|---|
| Founded | 2017 | 1969 |
| Country | Israel | United States |
| Employees | 15 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 32.4M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | NRSN | RAND |
|---|---|---|
| Price | $0.86 | $11.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 125.0K | 4.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.29% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $10.05 |
| 52 Week High | $2.60 | $22.13 |
Technical Indicators
Market Signals| Indicator | NRSN | RAND |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 54.80 |
| Support Level | $0.85 | $10.31 |
| Resistance Level | $1.30 | $12.50 |
| Average True Range (ATR) | 0.06 | 0.50 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 42.21 | 78.29 |
Price Performance
Historical ComparisonAbout NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.